C
TVRD

Chescapmanager’s Tvardi Therapeutics TVRD Stock Holding History

Chescapmanager’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-47,281
Closed -$524K – 43
2024
Q3 		$524K Hold
47,281
– – 0.06% 35
2024
Q2 		$439K Hold
47,281
– – 0.04% 37
2024
Q1 		$1.55M Sell
47,281
-1,389
-3% -$36K 0.15% 37
2023
Q4 		$1.3M Sell
48,670
-125
-0.3% -$5.18K 0.13% 35
2023
Q3 		$2.95M Buy
48,795
+2,807
+6% +$263K 0.38% 35
2023
Q2 		$4.69M Buy
45,988
+13,755
+43% +$1.89M 0.73% 32
2023
Q1 		$5.7M Hold
32,233
– – 0.9% 31
2022
Q4 		$12.5M Hold
32,233
– – 2.92% 14
2022
Q3 		$10.9M Hold
32,233
– – 2.53% 15
2022
Q2 		$10.6M Sell
32,233
-417
-1% -$146K 2.5% 15
2022
Q1 		$14.3M Sell
32,650
-3,597
-10% -$1.48M 1.94% 17
2021
Q4 		$15.9M Hold
36,247
– – 2.12% 19
2021
Q3 		$20.2M Buy
36,247
+8
+0% +$4.01K 2.86% 9
2021
Q2 		$18.6M Sell
36,239
-278
-0.8% -$176K 2.04% 16
2021
Q1 		$28.5M Hold
36,517
– – 3.04% 8
2020
Q4 		$19.9M Buy
36,517
+9
+0% +$4.72K 2.42% 14
2020
Q3 		$16.7M Sell
36,508
-4,723
-11% -$2.74M 2.7% 16
2020
Q2 		$25.4M Buy
41,231
+4,970
+14% +$2.74M 4.27% 6
2020
Q1 		$17.2M Buy
36,261
+158
+0.4% +$85.9K 4.22% 11
2019
Q4 		$20.9M Buy
36,103
+1,597
+5% +$1.12M 3.08% 13
2019
Q3 		$22.7M Buy
34,506
+3,889
+13% +$3.23M 3.23% 10
2019
Q2 		$23.7M Sell
30,617
-2,801
-8% -$1.97M 2.36% 10
2019
Q1 		$23.6M Sell
33,418
-45
-0.1% -$26.9K 2.8% 8
2018
Q4 		$15.7M Hold
33,463
– – 3.78% 10
2018
Q3 		$28.9M Buy
33,463
+1,118
+3% +$807K 2.96% 5
2018
Q2 		$22.3M Buy
32,345
+3,097
+11% +$1.57M 2.58% 11
2018
Q1 		$13M Buy
29,248
+555
+2% +$269K 1.94% 19
2017
Q4 		$12.6M Buy
28,693
+279
+1% +$127K 2.06% 19
2017
Q3 		$14M Buy
28,414
+125
+0.4% +$62.6K 2.72% 15
2017
Q2 		$15.7M Buy
28,289
+3,473
+14% +$2.2M 2.64% 9
2017
Q1 		$16.4K Buy
24,816
+5,784
+30% +$3.09M 2.25% 7
2016
Q4 		$6.37M Buy
+19,032
New +$6.11M 2.34% 18

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Chescapmanager's TVRD Position: Q4 2024 in Review

Chescapmanager sold out of Tvardi Therapeutics (TVRD) in Q4 2024, closing a stake of 47,281 shares — an estimated $524K sold.

Chescapmanager first reported a position in TVRD in Q4 2016 and held it in 32 quarters. The position peaked at $28.9M in Q3 2018. 43 funds tracked by Wall St. Rank hold TVRD as of Q4 2024.

  • Chescapmanager reported no remaining Tvardi Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Chescapmanager sold 47,281 Tvardi Therapeutics shares in Q4 2024, an estimated $524K.
  • Chescapmanager first reported a position in Tvardi Therapeutics in Q4 2016 and held it in 32 quarters.
  • Chescapmanager's Tvardi Therapeutics position peaked at $28.9M in Q3 2018.
  • 43 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2024.

Based on Chescapmanager's 13F filing for Q4 2024, filed 14 Feb 2025.